To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 246 participants.
Also called NCT01068860
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 246 participants
- Sponsor
- Registry
-
NCT01068860
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Finland, Germany, India, Italy
- Registry status
- Completed
Technical summary
Registry record NCT01068860. Randomized; quadruple masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2010-08 (actual). Results posted on 2011-09-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Impaired Glucose Tolerance
- Intervention (Drug)
- Canakinumab 150 mg
- Intervention (Drug)
- Placebo to Canakinumab
- Lead sponsor
- Novartis
Record details
- Record id
cardio:ct-nct01068860- Content hash
4bb054b5254b92efdae87ccfd5e053ef05a3fd7def934ca49cbde720afbe04d8